Garth Lees-Rolfe

Former Chief Financial OfficeratInhibikase Therapeutics· In the 2024 proxy

Pay in FY2024Inhibikase Therapeutics stock +155.9% the same year

Garth Lees-Rolfe was paid $1.2M in FY2024 (Dec). Inhibikase Therapeutics stock rose 155.9% that year.

Pay$100 in the stock at the end of FY23 → $256

Pay is from the Summary Compensation Table of each Inhibikase Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

IKT
Inhibikase TherapeuticsPublic company · 2 yr
- Former Chief Financial Officer2024 – Present · 2 yrStock in role +32%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSV Download PNG How to use our data

Two people shown as one, or a wrong number?